Haha, in keeping with your constructive comment above - we're well past this being just a respiratory coronavirus, dummy.

And not sure I've ever heard of Pandora's Box where it mattered how much the box was open. The fact is it is open - and many people may be utterly screwed because of that - even the unvaxxed. So what are the solutions you (pl) suggest? "Grab the popcorn and watch"...sounds like a call for ignoring the issues and advocating for a no treatment route like they did with people who got covid early on.

What I'm suggesting is not running out and giving AdV vectored or any other jabs to everyone, it's that first of all we can't consider them as all being equal - re-read the quote I posted from the Irrgang paper. "This induction of IgG4 antibodies was not observed after homologous or heterologous SARS-CoV-2 vaccination with adenoviral vectors."

There's plenty of other evidence out there for non-specific effects (NSE) of vaccines (e.g. BCG vaccine on other viral infections) and if we see it here (with adenovirus having positive NSE and/or mRNA negative NSE w/regard to spike IgG4) should that data not be evaluated (or other data re-evaluated with that in mind)? Along those lines, I was re-acquainted with a paper (going down the rabbit whole w/Igor's post on the IgG4 matter) that suggested mrna "reprograms both adaptive and innate immune responses" ...https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1.full

One example, "The induction of tolerance towards stimulation with TLR7/8 (R848) or TLR4 (LPS) ligands by BNT162b2 vaccination may indicate a more balanced inflammatory reaction during infection with SARS-CoV-2", i.e. consistent with the notion of enhanced IgG4/spike 'tolerance'.

Those observations even mesh with the idea that things may need to be "retuned via epigenetic manipulation" perhaps with "small molecules that influence the right signaling pathways". Coincidentally, what I've found interesting is that unlike (m)any other whole virion vaccines, the adjuvant used in Covaxin is a small molecule toll-like receptor (TLR) 7/8 agonist. Initial results of the Phase 3 'immunobridging and broadening' trial are allegedly forthcoming sometime in January, so in that sense, no 'huge experiments' are needed (i.e. for a small molecule agonist). In this case it has been given to those who had received either mRNA or AdV primary series to evaluate seroconversion to other non-spike proteins, particularly the nucleocapsid. In my view what would be interesting is if the immune responses for those getting Covaxin as heterologous vaccination were on par with those of the vaccine naive, as there is evidence from both UK HSA Surveillance data and NIAID/Moderna paper (https://www.medrxiv.org/content/10.1101/2022.04.18.22271936v1) that the nucleocapsid seropositivty post-mrna vaccination appears to be diminished upon subsequent covid infection (i.e. potential adaptive immune suppression).

Who knows if these effects - e.g. stimulating broader immune response, the immune modulation giving rise to the IgG4 type responses, etc. - are coincident, but given the seeming ever increasing connections being found between the innate and adaptive immune systems, I think it may merit a closer look for having a possible remediative effect.

So yes, it could be possible that 'a' (not 'the') potential cure for bad 'vaccines' could be more vaccines. Would someone really close off the notion of using a 'vaccine' which actually might have the desired (secondary, non-specific) effect(s) out of spite because the original implementation of the broader vaccination campaign was such a shit show?